Novartis wins new use for Afinitor; Pfizer's Revatio gets pediatric nod;

@FiercePharma: Garnier pledges active role on Actelion board. News | Follow @FiercePharma

> Novartis' cancer drug Afinitor won the FDA's nod for a rare type of pancreatic cancer that has few treatment options. News

> Salix Pharmaceuticals posted a quarterly profit that beat market estimates, helped by higher sales from its flagship drug Xifaxan, which is used to treat travellers' diarrhea. Item

> Pfizer's Revatio won approval from the European Commission for the treatment of pediatric patients 1 to 17 years old with pulmonary arterial hypertension. Article

> The Centers for Medicare & Medicaid Services overpaid for dozens of drugs in 2009 by an estimated $4.4 million, the HHS Inspector General said. Story

> Australia's federal government is ignoring its own growth forecasts for the Pharmaceutical Benefits Scheme and making policy decisions without an evidence base, says industry. Report

> Shares of Savient Pharmaceuticals slid after the company posted a wider quarterly loss that missed estimates, prompting an analyst to downgrade the stock. Article

> Vanda Pharmaceuticals said that its profit fell 74 percent in the first quarter as it booked sharply lower royalty revenue and no product sales. Item

> Dusa Pharmaceuticals stock surged after the company said sales of its Levulan Kerastick skin treatment grew strongly for the second consecutive quarter. News

> Aesthetic laser device maker Solta Medical said it received FDA approval for its new anti-aging treatment, Clear + Brilliant. Story

Biotech News

 @FierceBiotech: Struggling Intercell replaces its CEO. Item | Follow @FierceBiotech 

 @JohnCFierce: Pfizer may still do bolt-ons: "pain, or in women's health, or in the vaccine area, or in oncology" Follow @JohnCFierce

> CRO Health Decisions offers to share risks on adaptive trials. News 

> Florida's biotech industry continues to grow. Article 

> Report: GSK has no plans to sell HIV unit. Story 

> Crown raises $28.8M for oncology work. News 

And Finally... Among the millions of men tested for prostate cancer each year, an increasing number are getting sick from potentially lethal, drug-resistant infections. Report